Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04838301 · ClinicalTrials.gov registry record · Phase 2

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

A Phase 2 study of Neurodegenerative Diseases and Alzheimer Dementia, sponsored by University of Arizona.

Recruiting
Registry status
Phase 2
Development phase
100
Enrollment target
10
Study locations

NCT04838301 is a Phase 2 study of Neurodegenerative Diseases and Alzheimer Dementia that is actively recruiting participants, run by University of Arizona. The registered enrollment target is 100 participants, below the 168,526-participant average among 12 other Neurodegenerative Diseases trials with a reported enrollment target (100% lower). The trial reports 10 study locations across 4 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04838301, a Phase 2 study of Neurodegenerative Diseases and Alzheimer Dementia, is actively recruiting participants, sponsored by University of Arizona.

RECRUITING
Registry status
Phase 2
Development phase
100 participants
Enrollment target
10
Study locations

Study Summary

A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.

Conditions Studied

Neurodegenerative Diseases Alzheimer Dementia Late Onset Alzheimer Disease

Interventions

  • OTHER Placebo
  • DRUG Allopregnanolone

Study Locations (10)

Florida

  • Optimus U Corporation - Miami
  • Miami Jewish Health - Miami
  • Combined Research Orlando - Orlando
  • Conquest Research - Winter Park

California

  • ATP Clinical Research - Costa Mesa
  • Wake Research-PRI, LLC - Los Alamitos
  • Syrentis Clinical Research - Santa Ana

Arizona

  • Perseverance Research Center - Scottsdale
  • University of Arizona / Clinical & Translational Sciences Research Center - Tucson

Massachusetts

  • MedVadis Research - Waltham

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-08-15
Est. Completion 2027-03-18
Phase Phase 2

Sponsor

University of Arizona

349 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04838301

The ClinicalTrials.gov registry entry for NCT04838301 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 168,526-participant average among 12 other Neurodegenerative Diseases trials with a reported enrollment target (100% lower). The listed sponsor is University of Arizona, which has 349 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Neurodegenerative Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT04838301 reports 10 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Arizona.

Frequently Asked Questions

What is clinical trial NCT04838301 about?

NCT04838301 is a clinical study titled "Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease". A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.

What is the current status of trial NCT04838301?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2023-08-15. Estimated completion is 2027-03-18.

What conditions does trial NCT04838301 study?

This clinical trial studies the following conditions: Neurodegenerative Diseases, Alzheimer Dementia, Late Onset Alzheimer Disease.

What interventions are being tested in trial NCT04838301?

The interventions under investigation include: Placebo (OTHER), Allopregnanolone (DRUG).

Who is sponsoring clinical trial NCT04838301?

This trial is sponsored by University of Arizona, which has 349 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04838301 being conducted?

This trial has 10 study locations across Arizona, California, Florida, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Neurodegenerative Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Neurodegenerative Diseases

All registered trials for this condition

Alzheimer Dementia

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.